New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.
Introduction Alemtuzumab (Campath-1 H) is currently the only monoclonal antibody monotherapy approved by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL). It is a humanized IgG1 monoclonal antibody that recognizes CD52. [1] [2] [3] The precise function of CD52 is not yet clear, but this antigen is expressed on essentially all B and T lymphocytes, as well as on natural killer cells, monocytes, macrophages, and eosinophils. 3 Alemtuzumab is thought to activate cell death by multiple mechanisms, primarily antibodydependent cellular cytotoxicity (ADCC) with some involvement from complement-dependent cytotoxicity (CDC), and apoptosis. 1, 4 Alemtuzumab does not directly target normal hematopoiesis since CD52 is not expressed on erythrocytes, neutrophils, platelets, or hematopoietic stem cells. This article reviews data from studies evaluating the utility of alemtuzumab for treatment of patients with CLL, and suggests how this agent may fit into a new CLL treatment paradigm by providing recommendations agreed upon by a panel of experts gathered to discuss this matter.
Alemtuzumab for fludarabine-refractory CLL
The activity of alemtuzumab in fludarabine-refractory CLL has been established in a multicenter study including 93 patients. 5 After an initial dose escalation to 30 mg, alemtuzumab was administered intravenously thrice weekly (TIW) for a maximum of 12 weeks. Famciclovir and trimethoprim sulfamethoxazole (TMP-SMX) were given as anti-infection prophylaxis beginning the second week of therapy and continued for at least 2 months after the end of treatment. The overall response rate, as assessed using the National Cancer Institute-sponsored Working Group (NCI-WG) criteria, 6 was 33%; two patients (2%) achieved a complete response (CR), 29 patients (31%) a partial response (PR), and 50 (54%) patients attained stable disease (SD). The median survival was 16 months for the group overall and 32 months for responders. Cytopenias improved in 42 (55%) of 76 patients with hematologic abnormalities at baseline and in 19 (44%) of 43 patients with SD after therapy. B-symptoms and fatigue resolved completely in 31 (53%) of 59 patients who presented with these symptoms at the start of therapy, including patients who achieved SD. Responses to therapy were observed in peripheral blood, bone marrow, liver, and spleen. Although almost two-thirds of patients with lymphadenopathy responded to alemtuzumab, resolution of lymphadenopathy depended on the size of the lymph nodes. Lymphadenopathy resolved in 64% and was improved by at least 50% in an additional 27% of patients with lymph nodes o2 cm in size, but no patients with nodes 45 cm had complete resolution of lymphadenopathy.
Infusion-related reactions, including rigors, fever, nausea, vomiting, and rash, were the most commonly reported adverse events, but these were primarily mild to moderate in severity and decreased with continuing alemtuzumab treatment. Infections developed in 55% of patients during the study; in 25 patients, these were grade 3 or 4. Responders to alemtuzumab developed significantly fewer grade 3 or 4 infections (three responders (10%) vs 22 nonresponders (36%); Po0.01). Reactivation of cytomegalovirus (CMV) was the most common opportunistic infection. 5 This pivotal trial established the efficacy and safety of alemtuzumab in patients with fludarabine-refractory CLL. The 32-month median survival among responders was a substantial improvement over the expected 10-12-month median survival historically observed in fludarabine-refractory patients (Figure 1 ). This study also identified a subset of patients who are unlikely to benefit from alemtuzumab monotherapy, such as those with bulky (45 cm) lymph nodes and poor performance status. The results of the pivotal trial were confirmed in another phase II study of 78 patients with lymphoproliferative disorders, of whom 42 (54%) had CLL. Responses were observed in 31% of patients with CLL and in 35% of all patients in the study. 7 Based on the data from the pivotal trial, alemtuzumab received an FDA indication as first-line therapy for fludarabine-refractory CLL.
Following FDA approval, studies were conducted to better characterize patients who may benefit from treatment with alemtuzumab. There is growing evidence that specific molecular subsets of patients with poor prognostic characteristics, notably those with 17p-abnormalities, may respond more favorably to alemtuzumab therapy. 8 These patients often show limited responses to treatment with either purine analogs or alkylating agents, and generally have poor survival rates. Alemtuzumab as first-line therapy for CLL Lundin et al 10 initiated a phase II trial evaluating alemtuzumab in first-line therapy for symptomatic patients with CLL. A small pilot study with nine patients had shown that alemtuzumab could be safely administered subcutaneously (n ¼ 4), with significantly fewer adverse effects than intravenous (i.v.) administration (n ¼ 5), but with comparable efficacy. 11 Since infusion-associated events had historically been an obstacle to initiating treatment with alemtuzumab, subcutaneous (s.c.) administration was selected for the first-line therapy trial. 10 A total of 41 patients received s.c. alemtuzumab 30 mg TIW for up to 18 weeks. In 38 evaluable patients, the response rate (based on NCI-WG criteria) was 87%, with 19% achieving CR and 68% PR. CLL was cleared from the peripheral blood in all but two patients after a median of 21 days. Overall, 79% of patients showed a response in bone marrow, with 45% achieving a morphologic and molecular CR (Figure 2a ). 10 Nodular PR (nPR) was seen in the bone marrow of 21% of patients. Although CLL cells were rapidly cleared from peripheral blood, s.c. alemtuzumab had to be continued for the full 18 weeks to achieve significant bone marrow responses in some patients, as illustrated in Figure 2b . 10 Median time to treatment failure has not been reached among responders, suggesting that up to 18 weeks of s.c. alemtuzumab may be necessary to achieve sufficient clearance of leukemic cells from bone marrow to realize an optimal response.
The importance of a prolonged duration of therapy was also supported by the pharmacokinetic data comparing alemtuzumab blood plasma levels after s.c. vs i.v. administration. 10, 12 In 30 relapsed patients treated with i.v. alemtuzumab and 20 patients from a previously untreated group receiving s.c. alemtuzumab, a higher cumulative dose was required to attain a plasma antibody level of 1 mg/ml. Higher blood concentrations correlated with better clinical responses. Since s.c. administration takes longer than i.v. administration to achieve similar plasma alemtuzumab levels, prolonged therapy may be necessary to ensure optimal plasma concentrations in peripheral blood, lymph nodes, and bone marrow. 10, 12 Subcutaneous alemtuzumab was well tolerated, with few systemic first-dose reactions compared with i.v. alemtuzumab. Injection-site reactions were seen in 90% of patients, but these were mild to moderate, often disappearing completely within 2 weeks of continued treatment. 10 Most patients participating in the trial were able to self-administer alemtuzumab after several weeks. Transient grade 4 neutropenia developed in 21% of patients. No episodes of febrile neutropenia or major (4grade 1) bacterial infections were diagnosed. CMV reactivation occurred in 10% of patients and resulted in fever without pneumonitis in four patients; all patients responded to i.v. ganciclovir.
Optimizing alemtuzumab efficacy through diverse therapeutic modalities

Alemtuzumab consolidation
Various therapeutic approaches have been pursued to determine whether administering alemtuzumab after initial chemotherapy Kaplan-Meier survival curve compared with survival in historical controls. Of 93 participating patients, 27 (29%) were alive at the 29-month follow-up. The median survival was 16 months (95% CI: 11.8-21.9 months). In total, 21 (68%) of 31 responders were still alive at the end of the study, and 42 (45%) of 93 patients survived more than 18 months. 5 
Figure 2
Response rates (%) by tumor site (a) and cumulative overall response (OR) rate (%) in relation to treatment duration (b) in B-CLL patients who responded to alemtuzumab therapy. 10 Role of Alemtuzumab in management of CLL patients S Faderl et al to eradicate minimal residual disease (MRD) would improve outcomes. O'Brien et al 13 studied the efficacy of alemtuzumab in achieving MRD after chemotherapy for CLL in a total of 41 patients. As shown in Table 1 , improvement in response to chemotherapy was observed in 46% of patients overall, and some of the patients who achieved CR with first-line therapy were able to achieve an MRD-negative CR (as measured by twocolor flow cytometry) after treatment with alemtuzumab. 13 As was previously observed, patients whose CLL did not respond to alemtuzumab typically had enlarged lymph nodes. Samples from 29 patients were analyzed by PCR for the presence of MRD; 38% of these achieved a molecular remission. Infusionrelated reactions were common but generally mild or moderately severe. However, 15 patients (37%) experienced infections; nine infections were related to CMV reactivation. 13 Table 2 ). In the first cohort of patients, two (4%) achieved a CR and 29 (52%) a PR after the fludarabine phase of therapy. Among 36 patients who entered the i.v. alemtuzumab phase of the trial, outcomes improved to 15 CRs (42%) and 18 PRs (50%) for an overall response rate of 92% (NCI-WG criteria). Of 11 patients with SD after fludarabine, three achieved CR and five had PR following alemtuzumab. Overall, of the 56 patients in the intent-to-treat population, the CR and PR incidences were 27 and 43%, respectively. 15 Patients with CLL who achieved at least a PR following initial therapy with either fludarabine alone or fludarabine and cyclophosphamide were randomized to observation or alemtuzumab 30 mg i.v. TIW for 12 weeks. Of the 11 patients randomized to alemtuzumab, three patients had CR and eight achieved PR 6 months after randomization, and five of six evaluable patients achieved a molecular remission. 15 In contrast, in the observation arm 6 months after randomization, CLL progressed in three of the 10 patients, and none of the patients was able to clear MRD in the peripheral blood. Furthermore, after a median follow-up of 31.3 months from the start of initial therapy, one patient in the alemtuzumab arm relapsed, compared with seven patients in the observation arm. 
Combining alemtuzumab
Administering several agents in combination may help overcome resistance to chemotherapy and take advantage of potential synergies in mechanisms of action. Studies have suggested that monoclonal antibodies may sensitize malignant cells to chemotherapy, and activating more than one apoptotic pathway through multiple agents may increase the potential for synergy. 16, 17 Alemtuzumab in combination with fludarabine has been shown to be effective in patients with advanced CLL. 17 In one study, six patients with advanced CLL refractory to single-agent therapy with either fludarabine or alemtuzumab alone were treated with fludarabine 25 mg/m 2 for 3 days every 28 days and alemtuzumab 30 mg TIW. Five of six patients not only demonstrated a response to this combination (one CR and four PR based on NCI-WG criteria) but also had better responses to combination therapy than to either agent alone. 17 In three patients, bone marrow examination revealed an absence of malignant cells, and two patients achieved MRD negativity. Furthermore, five patients remained alive at the 12-month follow-up. 17 These encouraging results of combined therapy with fludarabine and alemtuzumab suggest a need for further investigation of this combination. Alemtuzumab has also been combined with the anti-CD20 monoclonal antibody rituximab. 18 The rationale for combining these two immunotherapies was based not only on their potential synergistic effects, but also on the variable expression of CD20 and the suboptimal efficacy of single-agent monoclonal antibody therapy in patients with bulky lymphadenopathy (alemtuzumab) and in those with substantial bone marrow infiltration (rituximab). 18, 19 Faderl et al 18 combined rituximab with alemtuzumab in 48 heavily pretreated patients (median of four prior therapies) with lymphoproliferative diseases whose malignant lymphocytes expressed both CD20 and CD52. All patients received rituximab 375 mg/m 2 weekly for 4 weeks and alemtuzumab, which was dose escalated to 30 mg during week 1 and administered on days 3 and 5 of weeks 2-4. Among 32 patients with CLL, 20 demonstrated response (63%), including nine patients (28%) achieving CR in the bone marrow. 18 The combination was well tolerated, with most of the toxicitiespgrade 2. CMV antigenemia was positive in 13 patients (27%). Only seven patients (15%) were symptomatic, however, and all were successfully treated with ganciclovir. 18 
Maintenance therapy with alemtuzumab
In an attempt to prolong the time to disease progression, investigators in France compared standard alemtuzumab therapy with a novel maintenance regimen in patients with advanced CLL. 20 These patients received 30 mg doses of alemtuzumab TIW until they achieved a PR, then 30 mg of alemtuzumab once or twice every week for 1 month, and finally 30 mg per month for at least 4 months. The median duration of treatment was 4.5 months in the maintenance arm and 1 month for patients receiving the standard alemtuzumab regimen. Of 11 patients in the maintenance arm, nine (82%) responded with time to disease progression of 12.2 months. Median survival had not been reached after a median follow-up of 16 months. In contrast, three of five patients (60%) treated with the standard regimen achieved a response, with time to disease progression of 3 months and a median survival of 10 months (Po0.005). 20 The role of alemtuzumab as part of a maintenance strategy for high-risk CLL patients needs to be explored further.
Alemtuzumab safety
Management of infectious complications
Initial studies of alemtuzumab were conducted in patients with fludarabine-refractory CLL, a disease stage associated with poor prognosis and high infection rates. Rai et al observed major infections in 42% of 24 patients during alemtuzumab therapy. However, infection rates correlated with response, with only two of eight responders developing infections, compared with eight of 16 nonresponders. 21 Similar infection rates were noted in a study by Keating et al.
5,22
Perkins et al 23 retrospectively reviewed the frequency and severity of serious infections in fludarabine-refractory CLL. Of 27 patients with fludarabine-refractory disease who were receiving no therapy, 24 (89%) developed serious infections, which occurred at a median of 4 months after the onset of fludarabine refractoriness. Bacterial infections were most common, but atypical bacterial infections and viral infections were observed as well. This study highlights the significant risk of infection in patients with advanced-stage CLL.
Management of CMV reactivation
Since CLL patients are immunocompromised owing to advanced disease or prior therapies, the possibility of CMV reactivation is an issue that treating physicians need to consider. Hematology, December 7-11, 2001 , Orlando, FL; abstract 1540.) 24 Although organ involvement is rarely documented in patients receiving alemtuzumab, the panel of CLL experts recommended that oncologists consider the possibility of CMV reactivation in patients with a fever of unknown origin. Prompt diagnosis and treatment under these circumstances make CMV reactivation a manageable and reversible adverse event. (Sah A et al. Blood 2003; 102: 109a (abstract 372).) Guidelines for diagnosis and treatment are summarized in Table 3 . 24 Two issues related to CMV reactivation in patients receiving alemtuzumab remain debated. The first concerns the benefit of CMV-specific prophylaxis (eg, valganciclovir) during alemtuzumab therapy. Concerns over mandatory prophylaxis include additional myelosuppression and potential generation of CMV resistance. No data are currently available to recommend routine prophylaxis for CMV. Results of clinical studies comparing valganciclovir with routine antiviral prophylaxis in alemtuzumab-treated patients are eagerly awaited.
The second issue relates to screening for CMV prior to and during treatment. A number of investigators have advocated preemptive weekly PCR or CMV antigenemia screening. (Sah A, et al. Blood 2003; 102: 109a (abstract 372).) Others suggest that screening may be unnecessary, and patients should be tested for CMV reactivation only if they become symptomatic. CMV reactivation is rather predictable and most likely to occur during the nadir of CD4/CD8 cells, typically around the fourth to eighth week of alemtuzumab treatment. Prospective studies examining prompt diagnostic confirmation and treatment at the time of initial symptoms vs routine CMV monitoring are needed to adequately direct future care of CLL patients. The investigators present suggested that either approach is currently acceptable and future data from clinical trials may prompt revisiting this issue for more definitive recommendations.
These issues have sparked continued debate about the most appropriate recommendations for optimal management of CMV reactivation. Patients with unexplained fever should be tested for CMV by PCR or antigen detection assays. If the result is positive, treatment with ganciclovir or foscarnet is recommended. Some investigators choose to interrupt alemtuzumab therapy during treatment for CMV and restart therapy, if indicated, once CMV is cleared, whereas others continue alemtuzumab while treating CMV. Regardless, vigilant observation and prompt intervention remain crucial for effective management of any infection in CLL patients. 24 
Conclusions
In light of emerging data, previously established guidelines for the use of alemtuzumab in CLL required re-evaluation and updating. 24 These guidelines emphasize the importance of extending therapy with alemtuzumab beyond clearance of leukemia cells from the peripheral blood, as clearance of CLL from bone marrow, lymph nodes, and spleen is known to require longer treatment. Guidelines were also updated to help track possible emergence of CMV reactivation by monitoring patients for fevers of unknown origin, and treating them promptly with available antiviral agents (ie, valganciclovir, ganciclovir, foscarnet). The relative benefits of s.c. vs i.v. alemtuzumab administration are still under investigation, as are the benefits of alemtuzumab in combination regimens and in the consolidation or maintenance setting, and the optimal time point to initiate CLL therapy. This review aims to provide guidance for the optimal use of alemtuzumab in CLL. Adept integration of alemtuzumab into the therapeutic armamentarium may improve outcomes in patients with CLL. 
